Healthcare [ 11/13 ] | Biotechnology [ 91/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 24 | 0 Increased by +100% | -0.76 Increased by +100% |
| Mar 27, 24 | 0 Increased by +100% | -0.75 Increased by +100% |
| Nov 9, 23 | -0.65 Decreased by -10.17% | -0.63 Decreased by -3.17% |
| Aug 10, 23 | -0.81 Decreased by -52.83% | -0.85 Increased by +4.71% |
| May 11, 23 | -0.79 Increased by +73.49% | -0.68 Decreased by -16.18% |
| Mar 29, 23 | -0.61 Decreased by N/A% | -0.65 Increased by +6.15% |
| Nov 9, 22 | -0.59 | -0.59 |
| Aug 11, 22 | -0.53 | -0.46 Decreased by -15.22% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -16.71 M Decreased by -53.16% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -15.8 M Decreased by -63.28% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -14.61 M Decreased by -92.2% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -12.79 M Decreased by -69.48% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -10.91 M Decreased by -57.11% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -9.68 M Decreased by -93.31% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -7.6 M Decreased by -271.09% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 - | -7.54 M - | Decreased by N/A% - |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.